COVID-19 vaccines: key facts

The European Medicines Agency (EMA) continues to monitor the safety of vaccines against COVID-19 and to ensure that they offer protection in the European Union (EU), even though the public health emergency has ended. On this page you can find answers to key questions on the effectiveness and safety of COVID-19 vaccines in general, as well as on...

Last updated:
HumanCOVID-19
Public-health advice on COVID-19 medicines

Since the onset of the COVID-19 pandemic, the European Medicines Agency (EMA) has provided impartial advice to patients and healthcare professionals on the safe use of medicines, in particular in patients with or at risk of COVID-19 infection.

Last updated:
HumanCOVID-19
Nuvaxovid
COVID-19 Vaccine (recombinant, adjuvanted)
COVID-19 virus infection
Date of authorisation:
Revision: 12
Last updated:
MedicineHumanAuthorised
Xevudy
sotrovimab
COVID-19 virus infection
Date of authorisation:
Revision: 15
Last updated:
MedicineHumanAuthorised
Spikevax (previously COVID-19 Vaccine Moderna)
COVID-19 mRNA vaccine
elasomeran
elasomeran / imelasomeran
elasomeran / davesomeran
andusomeran
COVID-19 virus infection
Date of authorisation:
Revision: 45
Last updated:
MedicineHumanAuthorised
Bimervax
COVID-19 Vaccine (recombinant, adjuvanted)
COVID-19 virus infection
Date of authorisation:
Revision: 5
Last updated:
MedicineHumanAuthorised
International Coalition of Medicines Regulatory Authorities (ICMRA)

The European Medicines Agency (EMA) is a member of the International Coalition of Medicines Regulatory Authorities (ICMRA). ICMRA is a voluntary, executive-level entity of worldwide medicines regulatory authorities set up to provide strategic coordination, advocacy and leadership.

Last updated:
HumanCOVID-19Antimicrobial resistanceMedicines